Venolife gel d / nar. approx. 0.25% + 5% + 2% 40g tube

Release form, composition and packaging

?

Gel for external use 0.25% + 5% + 2% transparent or almost transparent, light yellow in color, with a specific odor.

100 g

sodium heparin on a dry matter basis 0.25 g (30,000 IU)

dexpanthenol in terms of 100% substance 5 g

troxerutin in terms of 100% substance 2 g

phenylethanol - 1 g, propylene glycol - 10 g, carbomer 940 or 980 - 0.8 g, trometamol - 0.4 g, purified water - up to 100 g. 40 g - aluminum tubes (1) - cardboard packs.

100 g - aluminum tubes (1) - cardboard packs.

pharmachologic effect

Combined preparation for external use, the pharmacological properties of which are due to the action of its constituent substances. Heparin is a direct anticoagulant, a natural anticoagulant factor in the body. It has an anti-inflammatory effect, promotes the regeneration of connective tissue by inhibiting the activity of hyaluronidase prevents thrombus formation, activates the fibrinolytic properties of blood, improves local blood flow. Dexpanthenol, a provitamin B5, is converted in the skin into pantothenic acid, which is a part of coenzyme A, which plays an important role in the processes of acetylation and oxidation. Improving metabolic processes, dexpanthenol promotes the regeneration of damaged tissues improves the absorption of heparin. Troxerutin is an angioprotective agent. Possesses P-vitamin activity, in particularreduces vascular tissue permeability and capillary fragility, promotes the normalization of microcirculation and tissue trophism, reduces congestion in veins and paravenous tissues, has antiexudative and anti-inflammatory effects.

Pharmacokinetics

When applied externally, the active substances are rapidly absorbed through the skin.

Heparin accumulates in the upper layers and actively binds to skin proteins, dexpanthenol penetrates into all layers of the skin and turns into pantothenic acid, troxerutin is found in the dermis in 30 minutes, and in the subcutaneous fatty tissue after 2-5 hours.

Indications for use

- edematous pain syndrome and microcirculatory-trophic disorders caused by venous insufficiency of the lower extremities (varicose veins, acute and chronic thrombophlebitis, post-thrombophlebitic syndrome, chronic lymphostasis)

- soft tissue injuries (hematomas, dislocations, sprains)

- to accelerate the granulation and epithelization of trophic ulcers in the regeneration phase (in the absence of pronounced exudation).

Contraindications for use

- open infected wounds or wounds with abundant exudation at the site of application

- children's age up to 1 year

- hypersensitivity to drug components.

Dosage regimen

The drug is used externally. The gel is applied in a thin layer to the affected area 2-3 times / day, evenly spreading over the skin surface with light rubbing movements until completely absorbed. The course of treatment is 2-3 weeks. The need for further treatment is determined by the attending physician, based on the severity of the pathological process and the results of clinical tests. In case of relapse of the disease, the course of treatment can be carried out 2-3 times a year. In case of trophic ulcers with weak exudation, before using the drug, the wound surface is cleaned of exudate and necrotic tissues, if necessary, washed with 3% hydrogen peroxide solution, furacilin solution 1: 5000 or 0.05% chlorhexidine bigluconate solution and dried. The gel is applied in a uniform thin layer so that the entire affected surface is covered with the preparation,and apply a sterile gauze bandage. Dressings are changed once a day. With an open method of treatment, the drug is applied 1-2 times / day. The duration of treatment is determined by the dynamics of epithelialization.

Overdose

Overdose is unlikely due to the low systemic absorption of the gel components.

Side effect

Allergic reactions: skin rash, itching (in place of n

Name ENG

VENOLIFE

Clinical and pharmacological group

The drug with antithrombotic, angioprotective, venotonic and improving tissue regeneration action for external use

ATX code

Heparin in combination with other drugs

Dosage

0.25% + 5% + 2% x 40g

Structure

Active substances: troxerutin 2g

dexpanthenol 5 g

sodium heparin 0.25 g (30,000 IU)

Excipients: phenylethyl alcohol, propylene glycol, carbomer 940 or 980, trometamol, purified water.

Indications

Edematous pain syndrome and microcirculatory-trophic disorders caused by venous insufficiency of the lower extremities (varicose veins, acute and chronic thrombophlebitis, post-thrombophlebitic syndrome, chronic lymphostasis)

soft tissue injuries (hematomas, dislocations, sprains)

to accelerate the granulation and epithelization of trophic ulcers in the regeneration phase (in the absence of pronounced exudation).

Storage conditions and periods

At a temperature of 15-25 degrees.

Expiration date: 2 years

INN / Active ingredient

troxerutin, dexpanthenol, sodium heparin

Contraindications

Hypersensitivity to Venolife components, open infected wounds or wounds with profuse exudation.

Specifications

Scope of the drug

Heart, vessels, blood

Release form

Gel

Manufacturer country

Russia

Package quantity, pcs

one

Way of introduction

On the skin

Vacation conditions

Without recipe

Brand name

Akrikhin

The amount of the dosage form in the primary package

40 g

Primary packaging type

Tuba

Type of consumer packaging

Pack of cardboard

Anatomical and therapeutic characteristics

C05BA53 Heparin sodium, in combination with other drugs

Dosage form

Gel for external use

Expiration date in days

730

Package weight, g

40

Category

:

Improving blood circulation

,

Angioprotectors and microcirculation correctors

,

Lipid-lowering drugs

,

Hematopoietic stimulants

Mode of application

:

Apply in a thin layer to the affected area and around it 2-3 times a day, evenly spreading over the skin surface with light rubbing movements until completely absorbed.

The course of treatment is 2-3 weeks.

The need for further treatment is determined by the attending physician, based on the severity of the pathological process and the results of clinical tests.

In case of recurrence of the disease, the course of treatment can be carried out 2-3 times a year.

Pharmaco-therapeutic group

:

Direct-acting anticoagulant for topical use + other drugs

Dosage (volume) of the substance in the preparation

:

sodium heparin in terms of dry matter 0.25 g (30,000 IU) < IR> dexpanthenol in terms of 100% substance 5 g < IR> troxerutin in terms of 100% substance 2 g

Information on technical characteristics, delivery set, country of manufacture